1 / 17

Cystic Fibrosis

Cystic Fibrosis. Gary Hoffman Wisconsin Newborn Screening Laboratory. Cystic Fibrosis Review. Most common lethal genetic autosomal recessive disorder Caucasians 1:3,000 African Americans 1:20,000 Hispanics 1:7,500 Asians 1:30,000 Multi-Organ dysfunction

elijah
Download Presentation

Cystic Fibrosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cystic Fibrosis Gary Hoffman Wisconsin Newborn Screening Laboratory

  2. Cystic Fibrosis Review • Most common lethal genetic autosomalrecessive disorder Caucasians 1:3,000 African Americans 1:20,000 Hispanics 1:7,500Asians 1:30,000 • Multi-Organ dysfunction digestive system reproductive system (males) respiratory tract • Clinical manifestations Irreversible lung damage (infections) Severe Malnutrition

  3. Cystic Fibrosis Review (Cont) • Life expectancy 50% die before age 32 • Significant morbidity at any age • Gene  Transmembrane Conductance Regulator (CFTR)  On long arm of chromosome 7 • lack of salt and water transfer across cell membranes  1,500+ mutations in the CFTR • Confirmatory diagnosis  Positive sweat chloride measurements

  4. Wisconsin Experience Randomized Control Trial (RCT)  1985 – 1990 Immunoreactive trypsinogen IRT cutoff – 99.8%tile False negative rate to high  1991 - 1994 Incorporated 2nd tier DNA F508del mutation Polyacrylamide gel with silver staining IRT cutoff – 98.5%tile Significantly reduced false negatives

  5. Wisconsin Experience (cont) Routine screening  July 1994 Two tiered algorithm 1st tier – Immunoreactive trypsinogen 2nd tier – Mutation analysis for F508del  Initial IRT cutoff for mutation testing – 94th%tile Changes  Increased percentile to 96th  Changed methodology Roche linear array 23 mutations Hologic (TWT) invader

  6. Mutation Analysis Issues • Problem Specimens • No product formation • Insufficient DNA • Excessive hemolysis - inhibits PCR • Transfusions • Delay in reporting results • 5 to 8 days depending upon PCR testing schedule

  7. Mutation Methods Targeted mutation analysis (most common)  Allele specific primers for wild type and mutant  bind and amplify small regions around mutation site  mutations can be substitutions, insertions, deletions

  8. Mutation Methods FDA approved kits:  Luminex (xTAG) Multiple Allele-Specific Primer Extension (ASPE) beads that generate signals when separated by laser flow cytometry. 39, 60, and 71 mutation panel Program for only ACMG 23 panel Open architecture Hologic – InPlex Flurorescence Resonance Energy Transfer (FRET) signal is generated with cleavase ACMG 23 Panel limited hands on time cartridge based

  9. Selection of CF mutations Over 1500 unknown mutations Technology can identify about 100 mutations Population demographics Match panel with genotypes 23 – 40 mutations will identify >95% of the cases Minimum Core – ACMG recommended 23  Disease causing mutations (R117H?) Panels do not need to cover 100% of the disease causing alleles

  10. Mutation Testing Summary Increase specificity and detection sensitivity Minimize false negatives Expedite management and treatment Identification of carriers

  11. Maple Syrup Urine Disease Gary Hoffman Wisconsin Newborn Screening Laboratory

  12. Overview of MSUD Aminoacidopathy of leucine metabolism Primary screening analytes – Leucine/Isoleucine & Valine Primary methodology – Tandem Mass Spectrometry Prevalence  Overall population – 1:250,000  Mennonite – 1:400 Clinical symptoms  seizures, coma, vomiting, sweet smelling urine, death, developmental delay Treatment: low protein diet Recommended treatment age: 72 hours from birth

  13. Maple Syrup Urine Disease

  14. Selection of Mutations Gene  Branched chain keto acid deydrogenase E1, alpha polypeptide (BCKDHA)  Long arm of chromosome 19 40 unknown mutations  Disrupt BCKD enzyme from breakdown leucine, valine, and isoleucine Mennonite populations  Y438N (Tyr438Asn)

  15. Wisconsin Method Tetra-primer ARMS-PCR  Two flanking primers; 2 internal primers  Two annealing temps  Concentrates the DNA fragments Amplicons separated on agarose gel  Homozygote – one band  Heterozygote – two bands

  16. Molecular Testing Advantages Support of the screening results Provide for earlier intervention High risk births – immediate testing Inexpensive testing

  17. MSUD SUCCESS STORY Couple known carrier of Y438N mutation Specimen collected at one hour of age Transported to NBS lab within 2 hours Assay setup immediately Result Y438N homozygote (8 hours of age) Dietary treatment at 12 hours of age Outcome One hospitalization in the first week of life Family compliant with therapy At 4 years - no mental or physical issues

More Related